Blueprint Medicines (BPMC) Price & Analysis

Compare

605 Followers

BPMC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$73.04 - $128.34

Previous CloseN/A

Volume168.58K

Average Volume (3M)3.87M

Market Cap

$8.27B

Enterprise Value$2.74B

Total Cash (Recent Filing)$576.24M

Total Debt (Recent Filing)$122.75M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Jul 30, 2025

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding64,666,115

10 Day Avg. Volume10,077,981

30 Day Avg. Volume3,865,626

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)5.08

Price to Sales (P/S)0.00

P/FCF Ratio-5.11

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue1.46

Enterprise Value/Gross Profit5.08

Enterprise Value/Ebitda-3.19

Forecast

1Y Price Target

$129.67

Price Target Upside1.14% Upside

Rating ConsensusHold

Number of Analyst Covering19

Blueprint Medicines News

See All News >

Bulls Say, Bears Say

Bulls Say

Acquisition StrategySanofi's announced acquisition of BPMC for $129/share plus CVRs complements Sanofi's existing footprint/portfolio in rare disease and immunology.

Financial ImpactSanofi expects the acquisition to be immediately accretive to gross margin and accretive to operating income and EPS after 2026.

Market ValidationThe transaction validates the opportunity in the indolent systemic mastocytosis market and the value of KIT agents, benefiting both the sector and Blueprint Medicines Corp.

Bears Say

Competitive ConcernsThe timing of the deal may suggest concerns about the quality of upcoming competitor data, motivating the execution of the deal ahead of the data announcement.

Macro IssuesMacro issues affecting biotech, such as pricing and tariffs, remain a concern for investors.

Safety RisksThere remains risk that larger BLU-808 trials will reveal a novel safety issue.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.53% Insiders

40.30% Mutual Funds

32.35% Other Institutional Investors

8.13% Public Companies and Individual Investors

Detailed Ownership Overview >

BPMC FAQ

What was Blueprint Medicines Corp.’s price range in the past 12 months?

Blueprint Medicines Corp. lowest stock price was $73.04 and its highest was $128.34 in the past 12 months.

What is Blueprint Medicines Corp.’s market cap?

Blueprint Medicines Corp.’s market cap is $8.27B.

When is Blueprint Medicines Corp.’s upcoming earnings report date?

Blueprint Medicines Corp.’s upcoming earnings report date is Jul 30, 2025 which is in 47 days.

How were Blueprint Medicines Corp.’s earnings last quarter?

Blueprint Medicines Corp. released its earnings results on May 01, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.496.

Is Blueprint Medicines Corp. overvalued?

According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Blueprint Medicines Corp. pay dividends?

Blueprint Medicines Corp. does not currently pay dividends.

What is Blueprint Medicines Corp.’s EPS estimate?

Blueprint Medicines Corp.’s EPS estimate is -0.44.

How many shares outstanding does Blueprint Medicines Corp. have?

Blueprint Medicines Corp. has 64,666,115 shares outstanding.

What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?

Blueprint Medicines Corp. reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went up 10.894%.

Which hedge fund is a major shareholder of Blueprint Medicines Corp.?

Currently, no hedge funds are holding shares in BPMC

Blueprint Medicines Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.71%

Trailing 12-Months

Asset Growth

15.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Blueprint Medicines Corp.

Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.

BPMC Company Deck

BPMC Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Despite some challenges in the first quarter and international markets, Blueprint Medicines shows strong performance with significant revenue growth, successful pipeline advancements, and a solid financial position. The sentiment is largely positive, driven by the strong market reception of AYVAKIT and increased revenue guidance.Read More>

BPMC Stock 12 Month Forecast

Average Price Target

$129.67

▲(1.14%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"$84","99":"$99","114":"$114","129":"$129","144":"$144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,99,114,129,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.79,128.96,130.13,131.3,132.47,133.64000000000001,134.81,135.98,137.15,138.32,139.49,140.66,141.83,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.79,127.93461538461538,128.07923076923078,128.22384615384615,128.36846153846153,128.5130769230769,128.65769230769232,128.8023076923077,128.94692307692307,129.09153846153845,129.23615384615383,129.38076923076923,129.5253846153846,{"y":129.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.79,126.03692307692309,124.28384615384616,122.53076923076924,120.7776923076923,119.02461538461539,117.27153846153847,115.51846153846154,113.76538461538462,112.0123076923077,110.25923076923077,108.50615384615385,106.75307692307692,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.56,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.18,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.54,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >